RGPX · As filed with the SEC
Regenerex Pharma income statement, by fiscal year
The statement as Regenerex Pharma presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
STATEMENTS OF OPERATIONS · USD, except per-share amounts
| USD, except per-share amounts | FY2024 Year ended Mar 31, 2025 | FY2023 Year ended Mar 31, 2024 | FY2023 Year ended Mar 31, 2023 | FY2022 Year ended Mar 31, 2022 |
|---|---|---|---|---|
| Operating Expenses: | ||||
| Selling, General and Administrative Expense | 1,163,618 | 1,065,825 | 96,171 | 126,267 |
| Research and Development Expense | 662,479 | 2,400,000 | — | — |
| Total Operating Expenses | 1,826,097 | 3,465,825 | 96,171 | 126,267 |
| Operating Gain (Loss) | (1,826,097) | (3,465,825) | (96,171) | (126,267) |
| Other Income (Expense): | ||||
| Interest expense | (320,047) | (80,638) | (66,788) | (59,063) |
| Foreign Currency Gain/Loss | 5,728 | 2,636 | 25,629 | (4,751) |
| Loss from theft | (383,908) | — | — | — |
| Income Tax Expense | (2,717) | — | — | — |
| Non-Operating Income (Expense) | (700,944) | (78,002) | (41,159) | (63,814) |
| Profit or Loss | — | — | (137,330) | (190,081) |
| Income from Discontinued Operations | — | — | — | (5,510) |
| Net Loss | (2,527,041) | (3,543,827) | (137,330) | (195,591) |
| Basic and Diluted Loss per Common Share – Continuing Operations | — | — | — | 0.00 |
| Weighted Average Shares Outstanding, Diluted | — | — | — | 183,414,030 |
| Basic and Diluted Loss per Common Share | (0.01) | (0.01) | 0.00 | — |
| Basic and Diluted Loss per Common Share – Discontinued Operations | — | — | 0.00 | — |
| Weighted Average Shares Outstanding | 278,727,759 | 277,653,029 | 277,112,660 | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.